Hemogenyx Pharmaceuticals PLC Director/PDMR Shareholding (1101T)
October 10 2017 - 1:00AM
UK Regulatory
TIDMHEMO
RNS Number : 1101T
Hemogenyx Pharmaceuticals PLC
10 October 2017
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Director / PDMR Shareholding
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology
company developing novel therapies to transform bone marrow and
blood stem cell transplantation, announces that it has been advised
that on 6 October 2017 Adrian Beeston, Non-Executive Director,
purchased 317,683 ordinary shares of GBP0.01 each in the Company
("Ordinary Shares") at a price of 3.1p per share. Following this
transaction Mr Beeston now has an interest in 5,731,969 Ordinary
Shares, representing approximately 1.61 per cent. of the Company's
issued share capital.
In addition, the Company has been advised that Peter Redmond,
Non-Executive Director, purchased 155,000 Ordinary Shares at a
price of 3.135p per share on 6 October 2017. Following this
transaction Mr Redmond now has an interest in 5,040,714 Ordinary
Shares, representing approximately 1.41 per cent. of the Company's
issued share capital, which includes shares held in the name of
Catalyst Corporate Consultants Limited of which Peter Redmond is a
director and sole shareholder.
The Notification of Dealing Forms provided in accordance with
the requirements of MAR in relation to the transactions listed
above are set out below:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
---- -----------------------------------------------------------------
a) Name Adrian Beeston
---- ------------------------------ ---------------------------------
2 Reason for the notification
---- -----------------------------------------------------------------
a) Position/status Non-executive Director
---- ------------------------------ ---------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------------ ---------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
---- -----------------------------------------------------------------
a) Name Hemogenyx Pharmaceuticals
Plc
---- ------------------------------ ---------------------------------
b) LEI n/a
---- ------------------------------ ---------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---- -----------------------------------------------------------------
a) Description of Ordinary shares of GBP0.01
the financial each
instrument, type
of instrument
----
Identification ISIN GB00BYX3WZ24
code
b) Nature of the Purchase of Ordinary Shares
transaction
---- ------------------------------ ---------------------------------
c) Price(s) and volume(s)
---- -------------- --------------
Price(s) Volume(s)
---- -------------- --------------
3.1p 10,000
-------------- --------------
d) Aggregated information
----
- Aggregated volume N/A - single transaction
- Price
e) Date of the transaction 6 October 2017
---- ------------------------------ ---------------------------------
f) Place of the transaction London Stock Exchange
---- ------------------------------ ---------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
---- -----------------------------------------------------------------
a) Name Peter Redmond
---- ------------------------------ ---------------------------------
2 Reason for the notification
---- -----------------------------------------------------------------
a) Position/status Non-executive Director
---- ------------------------------ ---------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------------ ---------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
---- -----------------------------------------------------------------
a) Name Hemogenyx Pharmaceuticals
Plc
---- ------------------------------ ---------------------------------
b) LEI n/a
---- ------------------------------ ---------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---- -----------------------------------------------------------------
a) Description of Ordinary shares of GBP0.01
the financial each
instrument, type
of instrument
----
Identification ISIN GB00BYX3WZ24
code
b) Nature of the Purchase of Ordinary Shares
transaction
---- ------------------------------ ---------------------------------
c) Price(s) and volume(s)
---- -------------- --------------
Price(s) Volume(s)
---- -------------- --------------
3.135p 155,000
-------------- --------------
d) Aggregated information
----
- Aggregated volume N/A - single transaction
- Price
e) Date of the transaction 6 October 2017
---- ------------------------------ ---------------------------------
f) Place of the transaction London Stock Exchange
---- ------------------------------ ---------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBSBDGSUGBGRC
(END) Dow Jones Newswires
October 10, 2017 02:00 ET (06:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024